Medical technology innovator OncoSil Medical (ASX:OSL) announced a comprehensive $8 million capital raising initiative.
The funding suite is strategically structured, featuring a $6 million institutional placement at $0.68 per share, complemented by a $2 million fully underwritten entitlement offer.
The financial influx is set to fortify the company’s balance sheet, bringing its pro-forma cash reserves to a robust $12 million.
The capital injection arrives at a critical inflection point for the company's commercial trajectory.
OncoSil is currently experiencing significant momentum across Europe, with fifteen hospitals in Spain, Italy, and Turkey consistently re-ordering its flagship device.
Perhaps most vital to its long-term valuation is the upcoming German Government sponsored study, scheduled to begin recruitment in the first half of 2026.
The trial alone is projected to generate $5.6 million in revenue, with an additional $6.5 million expected from treatments provided to ineligible patients within the study framework.
Further bolstering investor confidence is the support from Pengana High Conviction Equities Fund, acting as a cornerstone investor.
At the time of reporting, OncoSil Medical's share price was $0.72.